Performance analysis of healthcare-focused special purpose acquisition companies
-
DOIhttp://dx.doi.org/10.21511/imfi.18(4).2021.14
-
Article InfoVolume 18 2021, Issue #4, pp. 150-165
- 735 Views
-
397 Downloads
This work is licensed under a
Creative Commons Attribution 4.0 International License
The Covid-19 pandemic has accelerated some structural changes in the healthcare industry, and several health-tech start-ups thrived by providing innovative solutions to the challenges imposed by the pandemic. To finance their growth, many of these companies went through mergers with Special Purpose Acquisition Companies (SPACs). The paper investigates the market performance of healthcare-focused US-listed SPACs. The study aims to analyze the returns that healthcare SPACs offer to their investors and ascertain the determinants that drive these returns over a sample of 33 SPACs that merged with a healthcare firm between 2018 and 2021. Linear regression is employed to identify the drivers of SPACs’ market performance. Portfolio analysis is also performed and compared against the Russell 2000 and the S&P500 Healthcare Indexes.
The first outcome accomplished by the analysis is that a portfolio made of healthcare-SPACs underperforms small-cap firms by 2.14% and the healthcare industry by 6.72% over a two-year period, even if the difference in the returns of the healthcare SPACs portfolio and the two benchmarks is not statistically significant. Moreover, a high level of redemptions, the presence of serial SPAC sponsors, cross-border deals, private equity and venture capital funds as sellers, and a high percentage of boutique investment banks among the sell-side advisors seem to negatively affect the returns of healthcare-focused SPACs with a significance level of at least 10%. Instead, a larger number of buy-side advisors appears to be beneficial for healthcare-focused SPACs’ market performance.
- Keywords
-
JEL Classification (Paper profile tab)G12, G14, G24, G32, G34
-
References59
-
Tables6
-
Figures1
-
- Figure 1. Healthcare SPAC portfolio performance versus benchmarks
-
- Table 1. Overview of SPAC characteristics
- Table 2. Healthcare SPAC portfolio returns versus benchmarks
- Table 3. T-tests outcomes
- Table 4. Multiple linear regression output
- Table A1. Regressors’ correlation matrix
- Table A2. Variance inflation factors to detect multicollinearity
-
- Bai, J., Ma, A., & Zheng, M. (2021). Segmented Going-Public Markets and the Demand for SPACs”. SSRN.
- Bain & Company. (2021). Global Healthcare Private Equity and M&A Report 2021.
- Berger, R. (2008). SPACs: An Alternative Way to Access the Public Markets. Journal of Applied Corporate Finance, 20(3), 68-75.
- Blomkvist, M., & Vulanovic, M. (2020). SPAC IPO Waves. Economic Letters, 197, 109645.
- Blomkvist, M., Nocera, G., & Vulanovic, M. (2021). Who are the SPAC CEOs? SSRN.
- Boyer, C. M., & Baigent, G. G. (2008). SPACs as alternative investments. The Journal of Private Equity, 11(3), 8-15.
- Broude, P. (2007). Should you sell to a SPAC? Mergers & Acquisitions: The Dealmaker’s Journal, 42(5), 76-79.
- Collins, M. (2012). Special Purpose Acquisition Companies. Fordham Business Students Research Journal, 2(1), 3.
- Cruz, E., Stabinsky, N., Faery, R., Sharma, C., Kelley, R., Rutherford, A., Bahri, D., & Krasner, Y. (2020). Making Waves: the evolution of SPACs. Credit Suisse.
- Cumming, D., Haß, L., & Schweizer, D. (2014). The Fast Track IPO – Success Factors for Taking Firms Public with SPACs. Journal of Banking and Finance, 47, 198-213.
- Datar, V., Emm, E., & Ince, U. (2012). Going public through the back door: A comparative analysis of SPACs and IPOs. Banking & Finance Review, 4(1), 17-36.
- Davidoff, S. M. (2008). Black market capital. Columbia Business Law Review, 2008(1).
- Dealroom. (2021). Digital healthcare: patient-first?
- Deloitte. (2021a). 2021 global health care outlook.
- Deloitte. (2021b). SPACs find new prescription in health care.
- Dimic, N., Lawrence, E., & Vulanovic, M. (2020). The determinants of IPO Withdrawals: Evidence from SPACs. SSRN.
- Dimitrova, L. (2017). Perverse incentives of special purpose acquisition companies, the poor man’s private equity funds. Journal of Accounting & Economics, 63(1), 99-120.
- Floros, I. V. (2008). Two essays on alternative mechanism to going public (Doctoral Dissertation). The University of Pittsburgh.
- Floros, I. V., & Sapp, T. R. (2011). Shell games: On the value of shell companies. Journal of Corporate Finance, 17(4), 850-867.
- Gahng, M., Ritter, J. R., & Zhang, D. (2021). SPACs. SSRN.
- Gara, A., & Haverstock, E. (2020). How SPACs Became Wall Street’s Money Tree. Forbes.
- Gigante, G., & Guidotti, G. M. (2021). Do Chinese-focused U.S. listed SPACs perform better than others do? Investment Management and Financial Innovations, 18(3), 229-248.
- Gigante, G., Conso, A., & Bocchino, E. (2020). SPAC from the US to Italy: An evolving phenomenon. Italy: Egea Editore.
- Greenspan, R. (2021). Money for nothing, shares for free: a brief history of the SPAC. SSRN.
- Hale, L. M. (2007). SPAC: A financing tool with something for everyone. Journal of Corporate Accounting & Finance, 18(2), 67-74.
- Heyman, D. K. (2007). From Blank Check to SPAC: The Regulator’s Response to the Market, and the Market’s Response to the Regulation. Entrepreneurial Business Law Journal, 2(1), 531-552.
- Jenkinson, T., & Sousa, M. (2009). Why SPAC Investors Should Listen to the Market. Journal of Applied Finance, 21(2), 38-57.
- Jog, V., & Sun, C. (2007). Blank Check IPOs: A Home Run for Management. SSRN.
- Kim, H. (2009). Essays on Management Quality, IPO Characteristics and the Success of Business Combinations. Louisiana State University.
- Kim, H., Ko, J., Jun, C., & Song, K. R. (2021). Going public through mergers with special purpose acquisition companies. International Review of Finance, 21(3), 742-768.
- Klausner, M., & Ohlrogge, M. (2020). A sober look at SPACs (Stanford Law and Economics Olin Working Paper No. 559).
- Kolb, J., & Tykvová, T. (2016). Going public via special purpose acquisition companies: Frogs do not turn into princes. Journal of Corporate Finance, 40, 80-96.
- Lakicevic, M., & Vulanovic, M. (2013). A Story on SPACs. Managerial Finance, 39(4), 384-403.
- Lakicevic, M., Shachmurove, Y., & Vulanovic, M. (2014). Institutional Changes of Specified Purpose Acquisition Companies (SPACs). North American Journal of Economics and Finance, 28, 149-169.
- Lambert, J., & Malik, S. (2021). Why so many companies are choosing SPACs over IPOs. KPMG.
- Layne, R., & Lenahan, B. (2018). Special Purpose Acquisition Companies: An Introduction. Harvard Law School Forum on Corporate Governance.
- Lewellen, S. (2009). SPACs as an Asset Class. SSRN.
- Lohse, D. (1997). GKN Securities Agrees to Settle NASD Claims of Overcharging. The Wall Street Journal.
- McKinsey & Company. (2021). McKinsey on Healthcare: 2020 Year in Review.
- Michaels, D., & Osipovich, A. (2019). How a Nasdaq Loophole Fueled One Stock’s Rise of 3,750%. The Wall Street Journal.
- Nathan, A., Galbraith, G. L., & Grimberg, J. (2021). The IPO Spac-tacle. Goldman Sachs Global Macro Research, 95.
- NYSE. (2021). SPAC Growth and Sector Trends.
- Podder, S., & Hu, K. (2021). Telehealth startup Babylon to go public via $4.2 billion SPAC deal. Reuters.
- Pwc. (2021). SPAC overview and lifecycle.
- Ramkumar, A. (2021). The Celebrities From Serena Williams to A-Rod Fueling the SPAC Boom. The Wall Street Journal.
- Riemer, D. S. (2007). Special Purpose Acquisition Companies: SPAC and SPAN, or Blank Check Redux? Washington University Law Review, 85(4), 931-967.
- Rodrigues, U., & Stegemoller, M. (2012). Exit, Voice and Reputation: The Evolution of SPACs. Delaware Journal of Corporate Law, 37(3), 849-927.
- SEC Investor Alerts and Bulletins. (2021a). Celebrity Involvement with SPACs – Investor Alert.
- SEC Investor Alerts and Bulletins. (2021b). What You Need to Know About SPACs.
- SEC Public Note. (2021). Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”).
- Shachmurove, Y., & Vulanovic, M. (2018). SPAC IPOs. SSRN.
- Sharma, S., Fenton, B. K., & Khadavi, S. (2020). SPAC Lifecycle and Considerations for Private Companies. Bloomberg Law.
- Shrank, W. H., Rogstad, T. L., & Parekh, N. (2019). Waste in the US Health Care System. JAMA.
- Sjostrom, W. K. (2008). The Truth About Reverse Mergers. Entrepreneurial Business Law Journal, 2.
- Smith, E. (2021). Bill Ackman’s Pershing Square Tontine drops deal to buy 10% of Universal Music. CNBC Markets.
- SPAC Alpha. (2020). US SPAC Primer.
- Squire, K. (2020). Bill Ackman and Tontine Holdings rewrite the terms for SPACs. CNBC.
- The Business Research Company. (2021). Gene and Cell Therapy Global Market Opportunities And Strategies. BBC Research.
- Vulanovic, M. (2016). SPACs: Post-Merger Survival. Managerial Finance.